You are here: Industry Insights > multiple sclerosis

News List

Polpharma Biologics Announces FDA Approval of Tyruko® - First And Only Approved Biosimilar to Tysabri®* for Relapsing Forms of Multiple Sclerosis PharmaSources
August 28, 2023
On August 25, 2023,Polpharma Biologics announced today that the U.S. Food and Drug Administration (FDA) is the first regulatory body worldwide to approve the use of Tyruko®.
Polpharma Biologics Announces First-of-a-Kind Multiple Sclerosis Biosimilar Natalizumab Receives Positive CHMP Opinion PharmaSources
July 24, 2023
Polpharma biologics announces first-of-a-kind multiple sclerosis biosimilar natalizumab receives positive CHMP opinion.
Saol Therapeutics Announces FDA Approval of LYVISPAH™ (baclofen) Oral Granules and the Divesture of its Plasma-derived Hyperimmune Portfolio AmericanPharmaceuticalReview
December 09, 2021
Saol Therapeutics announced that the FDA has approved Saol's LYVISPAH™ (baclofen) oral granules.
Christina Applegate Announces She Has Multiple Sclerosis drugs
August 11, 2021
Emmy award-winning actress Christina Applegate revealed Monday night that she is battling multiple sclerosis.
Qynapse to present clinical results of QyScore® for Alzheimer's Disease and Multiple Sclerosis at the 7th Congress of the European Academy of Neurology prnasia
June 16, 2021
QYNAPSE Inc., a medical technology company commercializing the most advanced artificial intelligence neuroimaging platform, today announced it will present clinical data on QyScore® for Alzheimer's disease and multiple sclerosis at the 7th Congress of ...
World Brain Day 2021 Dedicated to Multiple Sclerosis prnasia
May 20, 2021
The World Federation of Neurology (WFN) is pleased to announce that the theme of this year's World Brain Day is Stop Multiple Sclerosis.
UK launch for progressive multiple sclerosis mega-trial pharmatimes
May 08, 2021
The MS Society had announced that a world-first mega-trial for progressive multiple sclerosis (MS) will be launched in the UK later this year.
Novartis bags EU, UK licences for MS therapy Kesimpta pharmatimes
April 09, 2021
Novartis has received green lights from both the European Commission and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to market its multiple sclerosis (MS) therapy Kesimpta (ofatumumab).
Emerald Health Starts Activities for Initiation of Phase 2 Clinical Study in Multiple Sclerosis americanpharmaceuticalreview
March 11, 2021
Emerald Health Pharmaceuticals (EHP) has initiated activities for a Phase 2 international clinical study for the treatment of patients with multiple sclerosis (MS).
US FDA nod for Ocrevus (ocrelizumab) shorter 2-hour infusion for relapsing and primary progressive MS expresspharma
December 16, 2020
Approval based on data from the randomised, double-blind ENSEMBLE PLUS study, showing consistent safety to the conventional Ocrevus dosing regimen.

Previous page 1 2 3 4 5 6 Next page